The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells

The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells

Bibliographic Details
Main Authors:	Grozinsky-Glasberg, S, Rubinfeld, H, Gorshtein, A, Prais, M, Kendler, E, Feinmesser, R, Grossman, A, Shimon, I
Format:	Conference item
Published:	2009

Similar Items

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
by: Grozinsky-Glasberg, S, et al.
Published: (2010)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
by: Druce, M, et al.
Published: (2012)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.
by: Druce, M, et al.
Published: (2012)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
by: Grozinsky-Glasberg, S, et al.
Published: (2011)

Preliminary Report of the Use of Everolimus in a Patient with Progressive Medullary Thyroid Carcinoma
by: Druce, M, et al.
Published: (2010)

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
by: Druce, MR, et al.
Published: (2009)

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
by: Dworakowska, D, et al.
Published: (2009)

Structure of the human mTOR Complex I and its implications for rapamycin inhibition
by: Yip, Calvin K., et al.
Published: (2012)

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
by: Wagle, N., et al.
Published: (2015)

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
by: Cavazzoni, A, et al.
Published: (2012)

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
by: Cavazzoni, A, et al.
Published: (2012)

mTOR signalling and metabolic regulation of T cell differentiation.
by: Peter, C, et al.
Published: (2010)

The identification of the mTOR-regulated phosphoproteome and a mediator of feedback inhibition to P13K-Akt
by: Hsu, Peggy Ping
Published: (2011)

Adrenocortical Cancer: A Therapeutic Approach with Everolimus (RAD001)
by: Gueorguiev, M, et al.
Published: (2010)

mTOR regulates memory CD8 T-cell differentiation.
by: Araki, K, et al.
Published: (2009)

The role of tryptophan and the mTOR pathway in T cell fate determination
by: Karydis, I, et al.
Published: (2014)

Effects of albumin–chlorogenic acid nanoparticles on apoptosis and PI3K/Akt/mTOR pathway inhibitory activity in MDA-MB-435s cells
by: Alzahrani, Badr, et al.
Published: (2023)

mTOR Signalling, Nutrients and Disease
by: Goberdhan, D, et al.
Published: (2008)

Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway deregulation and cause periventricular nodular heterotopia.
by: Broix, L, et al.
Published: (2016)

Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment.
by: Howie, D, et al.
Published: (2014)

mTOR Signaling in Growth Control and Disease
by: Laplante, Mathieu, et al.
Published: (2014)

An emerging role of mTOR in lipid biosynthesis
by: Laplante, Mathieu, et al.
Published: (2012)

mTOR Signaling in Growth, Metabolism, and Disease
by: Saxton, Robert Andrew, et al.
Published: (2018)

The mTOR pathway and integrating immune regulation.
by: Cobbold, S
Published: (2013)

The effects of mTOR inhibition in ischemic stroke
by: Schneider, AM
Published: (2022)

A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses
by: Bent, Eric H, et al.
Published: (2017)

Sodium alginate encapsulated iron oxide decorated with thymoquinone nanocomposite induces apoptosis in human breast cancer cells via PI3K-Akt-mTOR pathway
by: Alzahrani, Badr, et al.
Published: (2023)

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
by: Peterson, Timothy R., et al.
Published: (2015)

The TSC-mTOR pathway regulates macrophage polarization
by: Byles, Vanessa, et al.
Published: (2015)

A Central Role for mTOR in Lipid Homeostasis
by: Lamming, Dudley W., et al.
Published: (2016)

mTOR at the nexus of nutrition, growth, ageing and disease
by: Liu, Grace Y, et al.
Published: (2021)

mTOR and cancer: many loops in one pathway
by: Efeyan, Alejo, et al.
Published: (2012)

mTOR signalling and the regulation of Hoxp3 expression
by: Peter, C
Published: (2013)

Resistance mechanisms to mTOR inhibition in renal cancer
by: Earwaker, P
Published: (2015)

Nanocomposites of iron oxide, sodium alginate, and eugenol induce apoptosis via PI3K/Akt/mTOR signaling in Hep3 cells and in vivo hepatotoxicity in the zebrafish model
by: Elderdery, Abozer Y., et al.
Published: (2024)

Activation of the mTOR Signaling Pathway by L-Leucine in RPS14-Deficient Erythroid Cells
by: Yip, B, et al.
Published: (2012)

Insights into the regulation of mTOR signaling and the consequences of pharmacological inhibition
by: Thoreen, Carson Cornell
Published: (2009)

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
by: Carbonneau, M, et al.
Published: (2016)

Reversal of phenotypes of cellular senescence by pan-mTOR inhibition
by: Cox, L, et al.
Published: (2016)